Crossmark Global Holdings Inc. cut its position in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) by 12.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,370 shares of the company’s stock after selling 742 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Azenta were worth $252,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Commerce Bank lifted its stake in Azenta by 13.1% in the first quarter. Commerce Bank now owns 8,692 shares of the company’s stock valued at $388,000 after buying an additional 1,010 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in Azenta in the first quarter valued at $147,000. Royce & Associates LP lifted its stake in Azenta by 27.1% in the first quarter. Royce & Associates LP now owns 463,163 shares of the company’s stock valued at $20,666,000 after buying an additional 98,845 shares during the last quarter. Emerald Advisers LLC lifted its stake in Azenta by 61.6% in the first quarter. Emerald Advisers LLC now owns 4,765 shares of the company’s stock valued at $213,000 after buying an additional 1,817 shares during the last quarter. Finally, Trillium Asset Management LLC lifted its stake in Azenta by 2.7% in the first quarter. Trillium Asset Management LLC now owns 34,781 shares of the company’s stock valued at $1,513,000 after buying an additional 923 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on AZTA shares. Stephens raised their target price on Azenta from $45.00 to $55.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 9th. Raymond James started coverage on Azenta in a report on Tuesday, July 18th. They set a “market perform” rating on the stock. Finally, Needham & Company LLC raised their price target on Azenta from $55.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.
Insider Buying and Selling
In related news, insider David C. Gray sold 4,311 shares of Azenta stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $57.24, for a total value of $246,761.64. Following the transaction, the insider now owns 87,919 shares of the company’s stock, valued at approximately $5,032,483.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.67% of the stock is owned by corporate insiders.
Azenta Stock Performance
Shares of AZTA opened at $46.37 on Monday. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -89.17 and a beta of 1.51. Azenta, Inc. has a one year low of $36.01 and a one year high of $63.60. The stock’s fifty day moving average is $51.29 and its 200-day moving average is $47.59.
Azenta (NASDAQ:AZTA – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.16. The firm had revenue of $165.95 million for the quarter, compared to analyst estimates of $153.42 million. Azenta had a positive return on equity of 0.84% and a negative net margin of 6.09%. Azenta’s revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.12 earnings per share. Analysts forecast that Azenta, Inc. will post 0.21 EPS for the current fiscal year.
Azenta Profile
Azenta, Inc provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows.
Further Reading
- Five stocks we like better than Azenta
- How to Invest in Electric Cars
- Is domestic travel back on track? Check out these companies
- How to Find Undervalued Stocks
- MarketBeat Week in Review – 10/23 – 10/27
- What is the Australian Securities Exchange (ASX)
- Can casino stocks win big if economy slows?
Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
